References
- Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol (2009);8:464-74
- Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord (2011);26:399-406
- Poewe W, Antonini A, Zijlmans JC, et al. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging (2010);5:229-38
- Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol (2009);8:929-37
- Oertel WH, Berardelli A, Bloem BR, et al. Late (complicated) Parkinson’s disease. In: Gilhus NE, Barnes MP, Brainin M, eds. European Handbook of Neurological Management, 2nd edition Oxford, UK: Wiley-Blackwell (2011)
- Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord (2002);17:60-67
- Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson’s disease: effect on therapy decisions and quality of life. Mov Disord (2005);20:616-19
- Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson’s disease: a survey of patients and neurologists. Clin Drug Investig (2007);27:207-18
- Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson’s disease. Mov Disord (2004);19:513-17
- Setter SM. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease. Neurol Clin (2008);26(3 Suppl):S45-63,vi
- Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord (2005);20:1502-7
- Sawicki PT. [Patient-relevant end points: present state of the discussion at the Institute for Quality and Cost-Effectiveness in Public Health]. Dtsch Med Wochenschr (2006);131(19 Suppl 1):S16-20
- Onofrj M, Bonanni L, De Angelis MV, et al. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord (2009);15(Suppl 4):S85-92
- Chwieduk CM, Curran MP. Pramipexole extended release: in Parkinson’s disease. CNS Drugs (2010);24:327-36
- Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther (2012);34(4):966-78
- Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord (2005);20:1397-404
- Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009);24:826-32
- Sesar A, Arbelo JM, del Val JL. Treatment of Parkinson disease, time and dosage: ‘does simple dosage facilitate compliance and therapeutic goals?’ Neurologist (2011);17(6 Suppl 1):S43-6
- Levy G. The relationship of Parkinson disease with aging. Arch Neurol (2007);64:1242-6
- Shulman LM, Minagar A, Rabinstein A, Weiner WJ. The use of dopamine agonists in very elderly patients with Parkinson’s disease. Mov Disord (2000);15:664-8
- Politis M, Wu K, Molloy S, et al. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord (2010);25:1646-51
- Goole J, Amighi K. Levodopa delivery systems for the treatment of Parkinson’s disease: an overview. Int J Pharm (2009);380:1-15
- van der Eijk M, Faber MJ, Al Shamma S, et al. Moving towards patient-centered healthcare for patients with Parkinson's disease. Parkinsonism Relat Disord (2011);17:360-4
- Grosset KA, Grosset DG. Effect of educational intervention on medication timing in Parkinson’s disease: a randomized controlled trial. BMC Neurol (2007);7:20